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Abstract
Background: The immune system plays an important role in the multifactorial biologic system during the 
development of neoplasias. However, the involvement of the inflammatory response in the promotion/control of 
malignant cells is still controversial, and the cell subsets and the mechanisms involved are poorly investigated. The goal 
of this study was to characterize the clinical-pathological status and the immunophenotyping profile of tumor 
infiltrating lymphocytes and their association with the animal survival rates in canine mammary carcinomas.
Methods: Fifty-one animals with mammary carcinomas, classified as carcinomas in mixed tumors-MC-BMT = 31 and 
carcinomas-MC = 20 were submitted to systematic clinical-pathological analysis (tumor size; presence of lymph node 
and pulmonary metastasis; clinical stage; histological grade; inflammatory distribution and intensity as well as the 
lymphocytic infiltrate intensity) and survival rates. Twenty-four animals (MC-BMT = 16 and MC = 8) were elected to the 
immunophenotypic study performed by flow cytometry.
Results: Data analysis demonstrated that clinical stage II-IV and histological grade was I more frequent in MC-BMT as 
compared to MC. Univariate analysis demonstrated that the intensity of inflammation (moderate/intense) and the 
proportion of CD4+ (≥ 66.7%) or CD8+ T-cells (<33.3%) were not associated with worse survival rate. Multivariate 
analysis demonstrated that only lymphocytic infiltrate intensity ≥ 600 (P = 0.02) remained as independent prognostic 
factor. Despite the clinical manifestation, the lymphocytes represented the predominant cell type in the tumor 
infiltrate. The percentage of T-cells was higher in animals with MC-BMT without metastasis, while the percentage of B-
lymphocytes was greater in animals with metastasized MC-BMT (P < 0.05). The relative percentage of CD4+ T-cells was 
significantly greater in metastasized tumors (both MC-BMT and MC), (P < 0.05) while the proportion of CD8+ T-cells was 
higher in MC-BMT without metastasis. Consequently, the CD4+/CD8+ ratio was significantly increased in both groups 
with metastasis. Regardless of the tumor type, the animals with high proportions of CD4+ and low CD8+ T-cells had 
decreased survival rates.
Conclusion: The intensity of lymphocytic infiltrate and probably the relative abundance of the CD4+ and CD8+ T-
lymphocytes may represent important survival prognostic biomarkers for canine mammary carcinomas.
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Background
Spontaneous mammary tumors of female dogs have vari-
ous epidemiological, clinical, biological and genetic char-
acteristics that are similar to those in women [1]. Several
researchers have proposed the use of these tumors as
models for comparative studies with humans [2-6].
The development of malignant tumors is controlled by
a multifactorial biologic system that depends on genetic
abnormalities as well as the interplay between tumor
cells, stromal cells, and host inflammatory cells [7]. The
inflammatory process associated with neoplastic growth
involves a complex host response [8-10]. This response
includes the innate immune response, and the highly spe-
cific but more slowly developing adaptive or acquired
immune response, mediators and the interactions
between chemokines, cytokines and receptors [11-13].
In certain situations, the cells responsible for modula-
tion of the inflammatory response release chemokines
and cytokines that stimulate cellular proliferation and
angiogenesis, as well as inhibiting apoptosis, thus altering
the immune response to aggression [8,14,15]. There is
evidence that major inflammatory cytokines (such as IL-
1β, IL-6, IL-23 and TNF-α promote tumor development
b y  a c t i n g  d i r e c t l y  o r  i n d i r e c t l y  o n  n e o p l a s t i c  c e l l s
[10,15,16]. These factors together can accelerate muta-
genesis and promote the survival of atypical clones with a
greater capacity to invade tissues and organs [12].
Histological and immunohistochemical studies have
demonstrated that mammary carcinomas are effectively
infiltrated by different types of leukocytes, predominantly
macrophages and lymphocytes consisting mainly of T-
cells [17-19]. Initially, it was postulated that the presence
of the inflammatory infiltrate in the tumor site was evi-
dence of immune activity against the neoplastic growth.
The functional role of tumor-infiltrating lymphocytes in
dogs with mammary tumors is not yet fully established
[20].
Thus, there is no consensus regarding the effectiveness
of the anti-tumor response mediated by lymphocytes, or
by the predominant lymphocyte subpopulations [7,18-
22]. Nowak et al. (2007) [23] reported a correlation
between the number of CD8+ cells and the metastatic
potential of mammary adenocarcinomas in female dogs.
However, the inflammatory response associated with
mammary carcinomas and its relationship with prognos-
tic factors and the survival rate of female dogs has not
been studied.
Aiming to understand the dynamic interaction and the
association between host immune response and tumor
development, this study was to evaluate the immunophe-
notypic features of infiltrating lymphocytes in canine
mammary carcinomas and their relation to prognostic
factors and survival.
Methods
Groups of animals
Fifty-one female dogs with mammary neoplasias measur-
ing three centimeters or greater admitted at the Veteri-
narian Hospital of the Universidade Federal da Bahia
(UFBA) were selected between October, 2008 to August,
2009. The animals were purebreds or mixed-breed with
age ranging from of 8-18 years.
The tumor samples were classified based on the histo-
pathological diagnosis according to Misdorp et al. (1999)
[24] complemented by the proposal of Cassali et al (2002)
for classification of micropapillary carcinoma [25] and
the animals divided into two groups: i) carcinomas in
benign mixed tumors (MC-BMT, n = 31) and ii) carcino-
mas (MC, n = 20). Histological data revaluated that MC
group comprised distinct subtypes, including tubular (n =
3), papillary (n = 4), tubular-papillary (n = 3), solid (n = 4),
micropapillary (n = 3), anaplastic (n = 2) and one special
type referred as mucinous carcinoma, characterized by
abundant mucin production. The study series of carcino-
mas was a selected series consisting as simple and mixed
carcinomas exclusively.
Further categorization based on histological analysis of
lymph node was further used to categorize the tumor
samples into two subgroups referred as: i) (-) without
lymph node metastasis [MC-BMT (-), n = 19; MC (-), n =
10] and ii) (+) with lymph node metastasis [MC-BMT (+),
n = 12; MC (+), n = 10].
The clinical-pathological parameters, including tumor
size, lymph nodes metastasis, pulmonary metastasis,
clinical stage, histological grade, inflammation distribu-
tion and inflammation intensity, were used during com-
parative analysis between MC-BMT and MC.
Forty six animals were elected for the survival analysis
[MC-BMT (-), n = 18; MC-BMT (+), n = 12; MC (-), n =
09; MC (+), n = 07]. Five out of 51 animals were excluded
from the survival analysis because the owners have
decided for euthanasia of the animals due to the
advanced stage of the disease, the weakness of the ani-
mals or the impossibility of surgical excision, which was
certified by the clinical, laboratory and radiological evalu-
ations.
Twenty-four tumors samples were eligible for immuno-
phenotypic analysis, yielding at least 2 × 106 leucocytes,
including sixteen samples from the MC-BMT [MC-BMT
(-), n = 08; MC-BMT (+), n = 08] and eight from the MC
group [MC (-), n = 05; MC (+), n = 03].
After euthanasia, the diagnosis was confirmed by com-
plete necropsy and histopathological analysis. None of
the female dogs had prior use of anti-neoplastic drugs,
anti-inflammatory drugs or antibiotics within the 30 days
prior to surgical excision.
All procedures in this study were according to the
guidelines set by the Colégio Brasileiro de Experimenta-Estrela-Lima et al. BMC Cancer 2010, 10:256
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ção Animal (COBEA). This study was approved by the
Ethical Committee for the use of Experimental Animals
of the Universidade Federal de Minas Gerais, Brazil
(CETEA).
Clinical staging
The female dogs were initially submitted to a systematic
clinical examination along with macroscopic evaluation
of tumor and lymph nodes, histopathology of regional
lymph nodes and thoracic radiological examinations, in
order to accomplish a complete staging categorization.
Stage is determined from information on the size tumor
(T), involvement of regional lymph node (N) and the
presence or absence of distant metastases (M). Stages # II,
III, IV and V were defined based on TNM system previ-
ously describe by Owen, 1980 [26].
The clinical anamnesis was carried out by detailed eval-
uation of physiological parameters, analysis of historical
evolution and reproductive records along with biochemi-
cal and hematological analysis. The macroscopic evalua-
tion included determination of tumor features (size,
presence of inflammatory reaction and/or ulceration) and
location and analysis of regional lymph nodes by palpa-
tion. The confirmation of neoplastic involvement was
determined by histopathological analysis of inguinal and
axillaries lymph nodes. Thoracic radiological examina-
tions were performed in three planes (right lateral and
left lateral and ventral-dorsal) to search for lung metasta-
sis.
Upon suspect clinical diagnosis, forty-six female dogs
underwent surgical excision by mastectomy (regional or
radical depending on the tumor size, location and aspects
of the lymphatic drainage). Immediately after surgery, the
mammary chain was sent to the Department of Pathol-
ogy, at Universidade Federal da Bahia, for macroscopic
and microscopic characterization of the tumor features.
The forty six animals included in the survival rate anal-
ysis were submitted to quarterly follow-ups during twelve
months, including systematic clinical evaluation, radio-
logical examinations along with biochemical and hemato-
logical analysis. Survival rates were expressed in days
between the surgical excisions of the end of follow-up.
Tumor samples
The tumors were first classified according to size into two
groups: i) tumors measuring between 3-5 centimeters
and ii) tumors measuring more than 5 centimeters. In
cases with multiple nodules, the larger tumor size was
considered during the classification procedures. Follow-
ing classification, depending on the tumor size, three or
five fragments, representative of intratumor and periph-
eral tumor areas were randomly selected and removed
from each tumor. Necrotic areas were excluded. Tumor
fragments, measuring 1.5 × 1.5 cm, were submitted to
histological, morphological/morphometric and immuno-
phenotypic analysis.
Histological classification and grade
Fragments of the affected mammary gland that included
skin and subcutaneous tissues were fixed in phosphate
buffered 10% neutral formalin and processed by the rou-
tine technique of paraffin embedding. Histological sec-
tions (4 μm) underwent hematoxylin-eosin (HE) staining
[27]. In all cases, duplicate slides were prepared and ana-
lyzed by two veterinarian pathologists.
The histological classification was performed according
to the World Health Organization system (WHO) [24]
complemented by the proposal of Cassali et al (2002) for
classification of micropapillary carcinoma [25]. Tumors
with foci of malignant-appearing cells or distinct nodules
of such cell occurring in complex adenomas or benign
mixed tumors were diagnosed as carcinomas in benign
mixed tumors (MC-BMT). Tumors composed of one type
of malign cell either resembling luminal epithelial or
myoepithelial cells were diagnosed as carcinomas (MC)
[24]. Figure 1 shows representative images of MC-BMT
(Figure 1A) and MC in solid growth pattern (Figure 1B).
Histological grade was defined according to Elston and
Ellis (1991) [28] using 4 μm HE stained tissue sections.
For nuclear pleomorphism, the score #1 was used when
the nuclei were small, with little increase in size in com-
parison with normal breast epithelial cells, and had regu-
lar outlines and a uniformity of nuclear chromatin. The
score of #2 was assigned when the cells were larger than
normal, had open vesicular nuclei with visible nucleoli,
and showed moderate variability in size and shape. The
score #3 corresponded to marked variation in size and
shape, especially when very large and bizarre nuclei were
vesicular with prominent and often multiple nucleoli.
Figure 1 Histological diagnosis of canine mammary carcinoma 
samples. Low-power view of tumor specimen classified as carcinoma 
in benign mixed tumor (MC-BMT) associated with multifocal lympho-
cytic infiltrate, 200× (A); Higher power view of infiltrating lymphocytes 
in MC-BMT 600× (A-Inset); Low-power view of tumor specimen classi-
fied as mammary carcinoma (MC) in solid type associated with diffuse 
lymphocytic infiltrate, 200× (B). Histological sections (4 μm) underwent 
hematoxylin-eosin (HE) staining.Estrela-Lima et al. BMC Cancer 2010, 10:256
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Strict criteria for identification of mitotic figures were
employed according to Diest et al. (1992) [29]. Mitotic
activity was assessed as the number of mitosis cells per 10
fields, performed by two independent analysts in a
blinded fashion, using an Olympus BX-40 microscope fit-
ted to a 10× eyepiece and a 40× objective. Using this
equipment, one high power field visualizes an area of
0.239 mm2 [30]. Tumor up to 7 mitotic figures was scored
as 1 point, 8-16 mitotic figures as 2 points and more than
17 mitotic figures as 3 points. Final histological grade was
obtained by adding up the scores #1, #2 and #3 and classi-
fied as follows: i) grade I: 3-5 points, well differentiated;
ii) grade II: 6-7 points, moderately differentiated and
grade III: 8-9 points, poorly differentiated.
Morphological/morphometric analysis of tumor 
inflammatory infiltrate
The analysis of morphological aspects was carried out in
4 μm HE stained histological sections and the inflamma-
tory reaction classified by the distribution and by the
intensity. The distribution of inflammatory infiltrates
were evaluated in peripheral and intra-tumor areas and
classified as: i) focal: presence of 1-3 inflammatory foci;
ii) multifocal: presence of more than 3 inflammatory foci
and iii) diffuse: presence of inflammatory cells evenly dis-
tributed in the tumor section. The intensity of the inflam-
matory reaction was categorized into three subgroups
(discrete, moderate or intense) based on morphometric
analysis of total inflammatory infiltrate.
The morphometric analysis was carried out in eight
selected "Hot Spots" histological fields using an Olympus
BX-40 microscope fitted to a 10× eyepiece and a 40×
objective, representative of both peripheral and intra-
tumor areas. Morphometric analysis was assessed as the
number inflammatory cells per eight fields. Images were
captured using an oil immersion 100× objective (a digital
camera was adapted to an Olympus BX-40 microscope),
and the capture software SPOT version 3.4.5. The inflam-
matory cells were characterized by image analysis (Corel
Draw software version 7.468). Neutrophils, macrophages,
lymphocytes and plasma cells were identified based on
their morphological features and quantified in HE stained
sections. The eosinophils were identified and quantified
using additional analysis of Chromotrope 2R staining of
serial histological sections [31]. The total number of cells
was obtained by adding the eight fields analyzed. The
inflammatory infiltrate was first classified as: i) discrete:
presence of less than 500 inflammatory cells; iii) moder-
ate: presence of 500-1000 inflammatory cells and iii)
intense: presence of more than 1000 inflammatory cells.
The cut-off edges were determined based on the mean
number of cells. For data analysis, two intervals were
used considering the intensity of the lymphocytic infil-
trate: i) discrete + moderate (x< 600 lymphocytes) and ii)
intense (≥ 600 lymphocytes), respectively.
Immunophenotyping of tumor lymphocytic infiltrate by 
flow cytometry
Tumor fragments from twenty four dogs females, repre-
sentative of peri/intra-tumor areas were available for
i m m u n o p h e n o t yp i c  a n a l ys is  b y  fl o w  cyt o m e t ry  as  s u g -
gested by Teixeira-Carvalho et al., 2002 [32], modified as
follows: tissue fragments were immersed in cold RPMI
1640 (5 mL) in Petri dish and placed on ice for macera-
tion. The tissue were processed in tissue grinder and then
filtered on stainless steel gaze to obtain single cell suspen-
sion. The cell suspension was washed twice in RPMI-
1640 and ressuspended at a concentration of 1 × 107cells/
mL. Aliquots of 40 μL (4 × 105 cells) were incubated for
30 minutes at room temperature in the dark in 12 × 75
mm polystyrene tubes with 10 μL of previously diluted
monoclonal antibodies (mAbs), including: anti-canine
CD4-FITC or RPE 1:320 (rat-IgG2a, clone YKIX302.9),
anti-canine CD8-FITC or RPE 1:40 (rat-IgG1, clone
YCATE55.9) and anti-canine B cell-RPE 1:160 (Mouse
IgG1, Clone: CA2.1D6), all of which were produced by
Serotec (Oxford, UK). The combinations and dilutions of
mAbs were used as proposed by Araújo et al. (2008) [33].
After incubation, 1 mL of lysing solution (FACS brand
lysing solution, Becton Dickinson, San Diego, CA, USA)
was added to each tube while vortexing and incubated for
10 minute at room temperature in the dark. The negative
controls used were mAbs of the same isotype, produced
in the same species, and obtained from the same manu-
facturer. Stained cells were washed twice with 2 mL PBS
(phosphate buffered saline 0.15 M, pH 7.2) and then fixed
with 100 μL of FACS FIX solution (10.0 g/l paraformalde-
hyde, 10.2 g/l sodium cacodylate and 6.65 g/l sodium
chloride). A total of 10,000 events were run in a FACS-
Calibur flow cytometer, using the Cell Quest™software
(Becton Dickinson San Jose, CA, USA). Data analysis was
performed by first gating the lymphocyte population
based on their forward scatter (FSC) versus side scatter
(SSC) properties. Following, the immunophenotypic fea-
tures were analyzed on dual color FL1/FITC versus FL2/
R-PE dot plots. The results were expressed as percentage
of positive cells (T-cells and B cells) within gated lympho-
cytes and also as the relative percentage of CD4+, CD8+
T-cells and the CD4+/CD8+ T-cell ratio within gated T-
cells. In the survival analysis two intervals were consid-
ered for the relative percentages of CD4+ and CD8+ T-cell
subsets within gated T-cells: i) low (<66.7% of CD4+ T-
cells and ≥ 33.3% of CD8+ T-cells) and ii) high (≥ 66.7% of
CD4+ T-cells and <33.3% of CD8+ T-cells).
Statistical methods
Fisher's exact test was performed to verify the signifi-
cance of presumptive associations between categorical
variables. Data were grouped as follows: histological diag-
nosis (MC-BMT or MC); tumor size (3-5 cm or >5 cm);
lymph node metastasis (no or yes); pulmonary metastasisEstrela-Lima et al. BMC Cancer 2010, 10:256
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(no or yes); clinical stage (II, III, IV or V); histological
grade (I, II or III); inflammatory distribution (focal, mul-
tifocal or diffuse) and inflammatory intensity (discrete,
moderate or intense), lymphocytic infiltrate intensity
(<600 or ≥ 600 lymphocytes) as well as the relative per-
centage of CD4+  T-cells (≥ 66.7%) and CD8+  T-cells
(>33.3%).
For quantitative variables, Kolmogorov-Smirnov test
initially assessed the normality of distribution. Then, dif-
ferences between groups were assessed by Student's t /
Mann-Whitney's U tests (when two groups were com-
pared), or ANOVA/Kruskal-Wallis test (more than two
groups) whether parametric/non parametric samples
were evaluated, respectively. In the same way, possible
correlations were investigated by Pearson/Spearman
tests.
Survival curves were generated by Kaplan-Meier esti-
mation method and compared by Log-rank (Mantel-Cox)
or Cox proportional hazards tests in univariate or multi-
variate analysis, respectively. Groups were determined as
above.
In all instances, p value < 0.05 was considered to be sta-
tistically significant. Analyses were performed using the
softwares Prism 5.0 (GraphPad, San Diego, CA, USA) or
SPSS 17 (SPSS Inc., Chicago, IL, USA).
Results
Clinical and pathologic features
Comparative analysis of clinical and pathologic findings
between MC-BMT and MC are presented in Table 1. MC
was significantly associated with more frequent pulmo-
nary metastasis, advanced clinical stage and higher histo-
logical grade.
Morphologic and morphometric analysis
Inflammation was more frequently diffuse and intense in
MC than MC-BMT, but this association lack statistical
significance, as shown in Table 1.
Additional morphometry analysis revealed that lym-
phocytes were the predominant cell type, with signifi-
cantly higher number in comparison to the other
inflammatory cells (p < 0.001), except in the MC (-) sub-
group, where the number of lymphocytes and neutrophils
were similar (Figure. 2). No significant differences in the
number or percentage of lymphocytes were observed
between MC-BMT and MC groups (Figure. 2).
Further comparison between peripheral and intra-
tumor areas did not demonstrated any significant differ-
ences in the morphological and morphometric features of
the inflammatory infiltrates (data not shown).
Flow cytometric immunophenotyping of tumor infiltrating 
lymphocytes
In this study we have evaluated 24 tumors, 16 from the
MC-BMT and 8 from the MC group. The frequency of T
and B-lymphocytes as well as CD4+ and CD8+ T-cell sub-
sets and their ratio are shown in the Figure. 3A. Despite
no significant differences were observed between the
MC-BMT and MC groups, significant differences were
observed when comparing subgroups of animals catego-
rized based on the presence or absence of metastasis (Fig-
ure. 3B).
Data analysis demonstrate that MC-BMT(-) had signifi-
cantly higher (P < 0.05) percentage of T-cells in compari-
son to MC-BMT(+). On the other hand, significant (P <
0.05) higher percentage of B-lymphocytes were observed
in MC-BMT(+) in comparison to MC-BMT(-) (Figure. 4).
There were no significant differences in the percentage of
T and B-lymphocytes between the MC subgroups. The
relative percentage of CD4+ T-cells within the total T-
cells was significantly higher (P  < 0.05) in both MC-
BMT(+) and MC(+) (Figure 3B). Interestingly, the pro-
portion of CD8+ T-cells within the total T-cells was sig-
nificantly enhanced (P  < 0.05) both MC-BMT(-) and
MC(-) (Figure. 3B). These finding led to significant higher
(P < 0.05) CD4+/CD8+ T-cells ratio in both MC-BMT(+)
and MC(+) (Figure. 3B).
Survival curves comparison
The survival curves comparison stratified based on the
histological diagnosis, demonstrated significant (P  =
0.0014) lower values in the MC group as compared to
MC-BMT group (Figure. 4). Additional analysis revealed
that MC-BMT (-) and MC (-) had significantly (P = 0,009
and P = 0,033, respectively) higher survival rates as com-
pared to MC-BMT (+) and MC (+) (Figure. 4). The mini-
mum survival was 25 days post surgery and the
maximum survival period was 307 days.
Additional analysis demonstrated that animals with
discrete/moderated tumor lymphocytic infiltrate (<600
lymphocytes) showed significantly higher survival rates
as compared to those with intense lymphocytic infiltrate
(≥ 600 lymphocytes) (P  = 0.0035) (Figure 5A). Similar
findings were observed in the analysis between MC sub-
groups (P = 0.022), with no differences observed between
MC-BMT subgroups (P = 0.0871) (Figure 5B).
Further analysis demonstrated that animals with tumor
infiltrating lymphocytes composition with higher relative
percentage of CD4+ T-cells and lower proportion of CD8+
T-cells had lower, but not significant (P = 0.191) survival
rate (Figure. 6A). Moreover, the correlation analysis
revealed that there was a significant (P = 0.0304) negativeEstrela-Lima et al. BMC Cancer 2010, 10:256
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association between the percentages of CD4+ T-cells and
the animal survival in days. Moreover, a positive correla-
tion was observed between the frequency of CD8+ T-cells
within the tumor infiltrating lymphocytes and the animal
survival in days (Figure. 6B).
Univariate analysis
Histological diagnosis of MC, tumor size > 5 cm, pres-
ence of lymph node or pulmonary metastasis, histological
grade II-III, multifocal inflammatory distribution, and
lymphocytic infiltrate intensity ≥ 600) displayed a nega-
tive association with animal survival (Table 2).
Multivariate analysis
Only lymphocytic infiltrate intensity ≥ 600 (coefficient =
4.1252; SE = 1.8260; OR = 61.8804; confidence interval =
1.7268-2,271.4921; P = 0.0239) remained as independent
prognostic factor of survival rates in the final model
(Table 2).
Additional analysis demonstrated significant associa-
tion between lymph node metastasis (P = 0.04) and clini-
cal stage (P = 0.003) with distinct intervals of lymphocytic
infiltrate intensity (Table 3).
Discussion
The functional role of tumor-infiltrating lymphocytes in
canine mammary carcinomas is not yet fully established
and therefore the analysis of association between host
immune response and disease outcome may point out a
possible association between immunophenotypic fea-
tures of infiltrating lymphocytes and their relation to
prognostic factors and survival.
In this study, the percentage of T-lymphocytes was sig-
nificantly greater in the animals from the MC-BMT
group without metastasis, suggesting an effective protec-
tive role in preventing tumor development. In fast grow-
ing tumors, the presence of T-cells constitutes an
interesting prognostic indicator when compared with
non-immunogenic tumors, since their presence corre-
lates positively with the absence of metastasis in lymph
nodes, smaller tumor size, lower histological grade and
longer disease free survival time [7].
Additionally, our findings demonstrated that animals
from the MC-BMT group with lymph node metastasis
presented higher percentage of tumor infiltrating B-lym-
phocytes. The role of tumor infiltrating B-cells is still
controversial. Some studies have demonstrated that
chronic activation of B-cells contributes to tumor devel-
opment by inhibiting the activity of CD4+ T-cells by yet
unknown mechanisms [13]. However, our data demon-
strated that together with the enhanced levels of B-cells,
high frequency of CD4+ T cells was observed in animals
with worse prognosis in MC-BMT tumors. Moreover,
other studies have pointed out that, the acute activation
of B-cells may have a key role in early elimination of neo-
plastic cells, through the secretion of antigen-specific
immunoglobulins, thus participating in the regression of
tumors [7,11]. Together, these findings demonstrated that
the search for B-cell-related biomarkers to canine mam-
Table 1: Pathological and clinical status of mammary carcinomas in female dogs
Parameters Total
(n = 51)
MC-BMT
(n = 31)
MC
(n = 20)
Lymph node metastasis 43.0% (22/51) 39.0% (12/31) 50.0% (10/20)
Pulmonary metastasis 13.7% (07/51) 9.7% (03/31) 20.0% (04/20)
Histologic grade
Grade I 58.8% (30/51) 80.6% (25/31) 25.0% (05/20)
Grade II 29.4% (15/51) 19.0% (06/31) 45.0% (09/20)
Grade III 11.8% (06/51) 0.0% (0/31) 30.0% (06/20)
Size
3-5 cm 35.3% (18/51) 35.5% (11/31) 35.0% (07/20)
>5 cm 64.7% (33/51) 64.5% (20/31) 65.0% (13/20)
Clinical Staging
Stage II 29.4% (15/51) 29.0% (09/31) 30.0% (06/20)
Stage III 25.5% (13/51) 29.0% (09/31) 20.0% (04/20)
Stage IV 29.4% (15/51) 38.7% (12/31) 15.0% (03/20)
Stage V 15.7% (08/51) 3.2% (01/31)* 35.0% (07/20)
* Significant intragroup and intergroup difference at P < 0.05.Estrela-Lima et al. BMC Cancer 2010, 10:256
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mary carcinoma still needs further investigation to pro-
vide a more conclusive hypothesis.
Our data demonstrated that the enhanced proportion
of CD4+ T-cells besides the lower relative percentage of
CD8+ T-cells leading to higher CD4+/CD8+ T-cell ratio
observed in animals with metastasis may represent
another relevant biomarker to be used in follow-up stud-
ies. The maintenance of the CD4+/CD8+ T-cell ratio has
been pointed out as an important prognostic factor in the
progression of human breast cancer [34]. Additional lon-
gitudinal studies still need to be conducted to certify this
hypothesis.
In fact, the higher infiltration of CD4+  T-cells was
observed in the groups with the worst prognosis [MC-
BMT(+) and MC(+)], and was associated with tumor pro-
gression, metastasis and poor survival. Machetti and col-
leagues (2006) reported similar results and believe that a
greater percentage of CD4+ T-cells is correlated with the
induction of angiogenesis, secretion of immuno-inhibi-
tory cytokines and intra-tumor estrogen conversion [35].
On the other hand, regardless the tumor type, the
majority of animals displaying increased percentage of
CD8+ T-cells did not present metastasis. Therefore, our
findings suggest that the number of CD8+ T-cells may
represent a good complementary prognosis biomarkers,
since there was a significantly higher percentage of this
cell population in both groups MC-BMT(-) and MC(-),
suggesting that these cells have an inhibitory action,
either direct or indirect, in tumor progression that results
in increased animal survival. Similar results were
Figure 2 Composition of inflammatory infiltrate associated with canine mammary carcinoma. Infiltrating leukocyte populations from MC-BMT 
or MC (A), further subcategorized according to the absence (-) or presence (+) of lymph node metastasis (-) (B). The inflammatory cells were charac-
terized by image analysis as described in Material and Methods. Data were expressed as number of cells (#) per eight "Hot Spots" histological fields. 
Significant differences at p < 0.05 are highlighted by asterisk.
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observed by Leong and colleagues (2006) [36], assessing
the phenotypes of lymphocytes in ductal carcinomas in
women. However, Sheu et al. (2008) [34] observed a sig-
nificant correlation between the increase of CD8+ T-cells
and clinical staging in breast cancer. Likewise, Nowark
and colleagues (2007) [23] also reported a positive corre-
lation between the number of CD8+  T-lymphocytes
located in the tumor stroma and metastasis to lymph
nodes in female dogs suffering from mammary carci-
noma.
Tumor infiltrating T-lymphocyte may be involved in
distinct mechanism depending on the cell subset. It is
believed that while CD8+ T-cells play an important pro-
tective role controlling the tumor development, the CD4+
T-cells may present a dual role, participating with dichot-
omic specific immune response to the tumor, controlling
or inducing the tumor progression depending on the pro-
Figure 3 Immunophenotypic profile of tumor infiltrating lymphocyte in canine mammary carcinomas. Analysis of tumor infiltrating T-cells, B-
lymphocytes and T-cell subsets from MC-BMT or MC (A), further subcategorized according to the absence (-) or presence (+) of lymph node metastasis 
(-) (B). Lymphocyte populations and subsets were identified by flow cytometric immunostaining as described in Material and Methods. Data were 
expressed as percentage of positive cells within gated lymphocytes and CD4+/CD8+ T-cell ratio. Significant differences at p < 0.05 are highlighted by 
asterisk.
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duction of distinct cytokines patterns [8-11,37,38]. Some
studies have associated that the predominance of CD4+
T-lymphocytes in the tumor site is capable of "control-
ling" the expansion of CD8+ T-lymphocytes, thus inhibit-
ing an effective antitumor response [34]. This may
explain why some animals survived, despite the high
number of tumor infiltrating CD4+ T-cells. It is possible
that these CD4+ T-cells may synthesize pro-inflammatory
cytokines related to the protective anti-tumor immune
response. It has been demonstrated that the presence of
tumor-infiltrating lymphocytes in breast carcinomas
associated with the production of potentially anti-inflam-
atory cytokines, such as IL-4, IL-10, and TGF-β would be
associated with an immunomodulatory microenviron-
ment, triggering mechanism of tumor escape from the
immune system [17].
It is possible that the activation of both pro-inflamatory
CD4+ T-cells and cytotoxic CD8+ T-lymphocytes in ade-
quate proportions leads to an efficient immune response
that control the growth of tumor cells [39]. However, the
role of pro-inflamatory CD4+ T-cells in the tumor con-
trol is still controversial.
The presence of inflammatory cells in human tumors
has been linked by some researchers to an immune
response inefficient in preventing tumor development
[16,35,40]. There is evidence that some inflammatory
cytokines (such as IL-1β, IL-6, IL-23 and TNF-α promote
tumor development by acting directly or indirectly on
neoplastic cells [10,15,16]. It is possible that the balance
between pro- and anti-inflamatory cytokines is in fact
more relevant than the isolate analysis of a given
cytokine.
In our study, several clinic-pathological parameters
showed significant association with the survival rates,
including the histological type (MC), size (>5 cm), the
presence of lymph node and pulmonary metastasis, the
histological grade (II-III), the inflammatory distribution
(multifocal) and the lymphocytic infiltrate (≥ 600 lym-
Figure 4 Survival rates of animals with canine mammary carcinoma. Kaplan-Meier survival curves for animals from MC-BMT or MC (top panel), 
further subcategorized according to the absence (-) or presence (+) of lymph node metastasis (-) (bottom panels). Animals were submitted to quar-
terly follow-ups during twelve months and survival rates (%) expressed in days between the surgical excisions of the end of follow-up as described in 
Methods. The survival curves were estimated with the Kaplan-Meier method followed by Log-rank test and significant differences at p < 0.05 high-
lighted by asterisk.
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phocytes). These findings re-emphasize previous reports
that highlight the importance of monitoring these clinic-
pathological features in order to understand the biologi-
cal behavior of mammary cancer [41-48]. Although, these
parameters provide valuable information regarding diag-
nosis, prognosis and therapy [46,47], the lymphocytic
infiltrate intensity (>600) was the only prognostic factor
with independent association with lower survival rates in
our investigation.
The higher numbers of infiltrating lymphocytes, along
with the presence of metastasis were observed in the
groups of animals with lower survival rates. As the sur-
vival in days displayed a negative association with the %
of CD4+ T-cells and positive correlation with the % of
CD8+ T-cells, it is possible that the higher number of
infiltrating lymphocytes may reflected in higher number
of CD4+ T-cells and together these variables may be bio-
markers related to worse prognosis. On the other hand,
animals with lower of infiltrating lymphocytes, but those
with preferentially infiltration of CD8+ T-cells may pres-
ent better prognosis.
Conclusion
Our data demonstrated that from the immunophenotypic
standing point, the analysis of tumor infiltrating CD4+
and CD8+ T-cells may represent important complemen-
Figure 5 Survival rates of animals with canine mammary carcinoma. Kaplan-Meier survival curves for All (MC-BMT and MC) animals (A) catego-
rized according to the lymphocytic infiltrate intensity (<600 and ≥ 600 lymphocytes) further sub grouped according to the histological diagnosis (MC-
BMT or MC) (B) (bottom panels). Animals were submitted to quarterly follow-ups during twelve months and survival rates expressed in days between 
the surgical excisions of the end of follow-up as described in Methods. The survival curves were estimated with the Kaplan-Meier method followed 
by Log-rank test and significant differences at p < 0.05 highlighted by asterisk.
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Figure 6 Survival rates of animals with canine mammary carcinoma. Kaplan-Meier survival curves for animals for All (MC-BMT and MC) animals 
categorized according to the relative percentage of CD4+ T-cells (<66.7% or ≥ 66.7%) and CD8+ T-cells (≤ 33.3% or >33.3%) (A). Animals were submit-
ted to quarterly follow-ups during twelve months and survival rates expressed in days between the surgical excisions of the end of follow-up as de-
scribed in Methods. The survival curves were estimated with the Kaplan-Meier method followed by Log-rank test. Correlation analysis highlighted the 
significant association between the percentages of CD4+ T-cells and CD8+ T-cells with the animal survival in days (B).
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Table 2: Univariate and multivariate analysis of clinical-pathological parameters associated with low survival rates.
Parameters Analysis (P value)
Univariate Multivariate
Histological diagnosis (MC) 0.05* 0.18
Size (>5 cm) 0.03* 0.18
Lymph node metastasis (Yes) 0.003* 0.09
Pulmonary metastasis (Yes) < 0.0001* 0.39
Histological grade (II-III) 0.007* 0.42
Inflammatory distribution (multifocal) 0.04* 0.07
Inflammatory intensity (moderate/intense) 0.71 ND
Lymphocytic infiltrate ((600 lymphocytes) 0.002* 0.02*
% of CD4+ ((66.7%), CD8+ T-cells (<33.3%) 0.12 ND
* Selected for multivariate analysis. ND = not done. The end point was the animal death or discharge during the follow-up periodEstrela-Lima et al. BMC Cancer 2010, 10:256
http://www.biomedcentral.com/1471-2407/10/256
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tary prognosis biomarkers to be further investigated in
canine mammary carcinomas. The higher percentage of
infiltrating CD4+ T-cells was observed in animals with the
worse prognosis, including those with lymph node
metastasis and lower survival in days. Moreover, the per-
centage of infiltrating CD8+ T-cells was correlated with
absence of metastasis and higher survival span in canine
mammary carcinomas. The importance of B-cells as a
prognostic biomarker still remain to be elucidated, may
be approaching further analysis of B-cell subsets and their
activation status.
Furthermore, additional studies are still needed to
expand our understanding of the complex mechanisms
involved in the function and interaction of infiltrating
CD4+ T-lymphocytes, their cytokine biosynthesis, as they
relate to increased malignancy and metastasis, and of the
role played by CD8+ T-cells in inhibiting tumor develop-
ment, determining the tumor microenvironment that
favor the control mechanisms in canine mammary carci-
nomas.
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